Skip To Main Content
Abhijit Barve on Muck Rack

Abhijit Barve

As seen in: Color Research & Application, JAMA (The Journal of the American Medical Association), 3BL Media, Wallstreet Online, FinanzNachrichten.de, BioPharma Dive, CRWE World, Central Charts
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Abhijit

Contact Abhijit, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial

|
By Susan B. Bressler, Abhijit Barve, Katrin M. Beckmann, Prasanna C. Ganapathi
| JAMA (The Journal of the American Medical Association) Verified
Key Points Question Is the efficacy of MYL-1701P, an aflibercept biosimilar, equivalent to reference aflibercept with comparable safety for diabetic macular edema (DME)? Findings In this randomized clinical trial including 355 participants, MYL-1701P was equivalent to reference product aflibercept in managing diabetic macular edema.
Open in Who Shared Issue with article?

Transforming MS care to meet patient needs

|
By Abhijit Barve
| BioPharma Dive Verified
Abhijit Barve, MD, PhD, MBA is the Chief Medical Officer at Viatris in Canonsburg, Pennsylvania. He earned his medical degree from University of Mumbai, India and his PhD in Biopharmaceutical Sciences from University of Illinois, Chicago. He later went on to get his MBA from the Booth School of Business in Chicago.
Open in Who Shared Issue with article?

Viatris: Making a Difference for Those Impacted by Drug-Resistant Tuberculosis

|
By Abhijit Barve
| FinanzNachrichten.de
NORTHAMPTON, MA / ACCESSWIRE / September 15, 2023 / Viatris By: Abhijit Barve Viatris at UNGA Tuberculosis (TB) remains one of the world's deadliest infectious diseases, second only to COVID-19, claiming 1.6 million lives worldwide in 2021.1 TB generally affects the most vulnerable people - those who live in poverty, are marginalized or economically and socially excluded.2 Ongoing conflicts across Eastern Europe, Africa and the Middle East have further exacerbated this situation.3 Globally,...
Open in Who Shared View Duplicates (10) Issue with article?
See all 13 articles